Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery

With over 490,000 multidrug-resistant tuberculosis cases (MDR-TB; TB caused by Mycobacterium tuberculosis resistant to at least isoniazid and rifampicin) occurring globally each year, 6.2% of which are XDR-TB (extensively drug-resistant TB: MDR-TB with additional resistance to fluoroquinolones and one second-line injectable), the ‘white plague’ remains a major clinical and public health priority.1–4

Source: Journal of Infection - August 7, 2018 Category: Infectious Diseases Authors: Sergey E. Borisov, Lia D'Ambrosio, Rosella Centis, Simon Tiberi, Keertan Dheda, Jan-Willem Alffenaar, Rohit Amale, Evgeny Belilowski, Judith Bruchfeld, Barbara Canneto, Justin Denholm, Raquel Duarte, Aliasgar Esmail, Alex Filippov, Lina Davies Forsman, Mi Source Type: research